2023 Southern Hemisphere Influenza Vaccine
Closed Pre-Solicitation Posted
Not the latest version. See the latest solicitation from .
- Solicitation number
- SPE2DP22R0005
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support is seeking sources capable of providing 60,000 doses of Southern Hemisphere Influenza Vaccine for the 2023 season. The vaccine must be a quadrivalent vaccine licensed by the FDA and intended for active immunization of individuals aged 6 months and older. Each pre-filled 0.5mL dose syringe must be free of thimerosal and other preservatives, shipped refrigerated between 2-8 degrees Celsius, and delivered to the Defense Distribution Center in Susquehanna, PA. Responses to this request for information are due by August 1, 2022 and will be kept confidential as allowed by law.
There is no set-aside designated for this procurement. Current annual capacity and technical capabilities for vaccine manufacturing should be detailed in responses, including place of manufacture, FDA registration information, product descriptions and pricing. Firms currently developing vaccines or with relevant production capabilities are invited to submit information that will be protected under the Critical Infrastructure Information Act.
Notice text
The Defense Logistics Agency- Troop Support is seeking sources capable of providing Southern Hemisphere Influenza Vaccine. Shall be a quadrivalent vaccine, licensed by the FDA, intended for active immunization for the prevention of influenza for the Southern Hemisphere. Shall meet the minimum formula for the influenza vaccine as determined by the FDA’s Vaccines and Related Biological Products Advisory Committee. Shall be a pre-measured 0.5ML dose, each dose shall be pre-filled in a commercially available syringe for intramuscular administration in healthy individuals aged 6 months and older. Shall be free of thimerosal or other preservatives. Shall be shipped refrigerated between 2° and 8° C. The vaccine must not be frozen. Shall be one package containing 10 pre-filled syringes as the unit of issue. Product shall be both FDA Approved and ACIP Recommended.
DLA Troop Support has an annual estimated requirement for Southern Hemisphere Influenza Vaccine of 60,000 doses for the 2023 season. The vaccine shall be delivered to the Defense Distribution Center (DDC) in Susquehanna, PA.
This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to the RFI. All submitted information shall remain with the U.S. Government and will not be returned.
*** Currently Marketed Southern Hemisphere Influenza Vaccine ***
If your firm currently markets Southern Hemisphere Influenza Vaccine, please provide information with respects to the following:
- Place of Manufacture
- Estimated Annual Capacity
- FDA registration information
- Product Name and description including description of any special features
- Current unit sale price
- Estimated inventory level and storage requirements
- Delivery days for this item
- Capacity for surge and sustainment requirement
- Country of Origin for API
*** New Products Under Development ***
For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture product described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protect Critical infrastructure information (PCII) Program outlined in the Critical Infrastructure Information Act 2002.
Your response to this RFI may be submitted electronically in pdf format and emailed to the Contracting Specialist yu.chen@dla.mil.
Notice history
| Notice | Type | Posted |
|---|---|---|
| 2023 Southern Hemisphere Influenza Vaccine | Limited / Sole Source Justification | |
| 2023 Southern Hemisphere Influenza Vaccine - Solicitation | Solicitation | |
| 2023 Southern Hemisphere Influenza Vaccine | Pre-Solicitation | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response | Office of the Assistant Secretary for Preparedness and Response | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity